Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More
Listen to this article on the DDW Podcast: Genoscience Pharma’s Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins. Cancer relies on palmitoylation for progression Palmitoylation is a global post-translational lipid modification, that controls the localisation, stability, and function of several proteins. Read More
Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers. The pioneering encyclopaedia, or ‘Rosetta Stone’, of sarcoma biology compiles a wealth of… Read More
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More
This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More
Researchers from the University of Liverpool, UK, have created a biomedical compound that has the potential to stop the spread of breast cancer. Scientists from the Chemistry and Biochemistry Departments at the University of Liverpool and Nanjing Medical School in China have discovered a possible way… Read More
Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal… Read More
Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated… Read More
A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More
Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova… Read More
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the… Read More
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that… Read More
Germo Gericke, Ariceum Therapeutics, tells DDW's Megan Thomas about his work in radiopharmaceuticals for the treatment of cancer and offers valuable advice to others in this field. 1. Where do you work, and can you tell us what you’re working on at the moment? I am the Chief Medical Officer… Read More
Listen to this article on the DDW Podcast: Evan Floden, CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are starting to be placed front and centre of… Read More
Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields,… Read More
